The company announced a licensing deal that will allow the drug, molnupiravir, to be made and sold cheaply in 105 developing nations.
Author: Stephanie Nolen
Gates Foundation Pledges $120 Million to Help Get Merck Covid Pills to Poor Countries
Regulatory hurdles and supply chain issues could slow efforts to produce generic versions of Merck’s antiviral molnupiravir for developing nations, despite licensing agreements.
Will New Covid Treatments Be as Elusive for Poor Countries as Vaccines?
Merck has taken a step to make its antiviral pill available in poor nations, but many obstacles remain for broad access to coronavirus drugs.
An Experimental H.I.V. Vaccine Fails in Africa
Researchers ended a large trial in South Africa after finding that an experimental vaccine offered little protection.